Literature DB >> 18083911

Trace amine-associated receptor 1 modulates dopaminergic activity.

Lothar Lindemann1, Claas Aiko Meyer, Karine Jeanneau, Amyaouch Bradaia, Laurence Ozmen, Horst Bluethmann, Bernhard Bettler, Joseph G Wettstein, Edilio Borroni, Jean-Luc Moreau, Marius C Hoener.   

Abstract

The recent identification of the trace amine-associated receptor (TAAR)1 provides an opportunity to dissociate the effects of trace amines on the dopamine transporter from receptor-mediated effects. To separate both effects on a physiological level, a Taar1 knockout mouse line was generated. Taar1 knockout mice display increased sensitivity to amphetamine as revealed by enhanced amphetamine-triggered increases in locomotor activity and augmented striatal release of dopamine compared with wild-type animals. Under baseline conditions, locomotion and extracellular striatal dopamine levels were similar between Taar1 knockout and wild-type mice. Electrophysiological recordings revealed an elevated spontaneous firing rate of dopaminergic neurons in the ventral tegmental area of Taar1 knock-out mice. The endogenous TAAR1 agonist p-tyramine specifically decreased the spike frequency of these neurons in wild-type but not in Taar1 knockout mice, consistent with the prominent expression of Taar1 in the ventral tegmental area. Taken together, the data reveal TAAR1 as regulator of dopaminergic neurotransmission.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18083911     DOI: 10.1124/jpet.107.132647

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  123 in total

1.  Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1.

Authors:  Cindy Achat-Mendes; Laurie J Lynch; Katherine A Sullivan; Eric J Vallender; Gregory M Miller
Journal:  Pharmacol Biochem Behav       Date:  2011-11-04       Impact factor: 3.533

2.  Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1).

Authors:  Gregory M Miller
Journal:  J Med Chem       Date:  2012-01-20       Impact factor: 7.446

3.  3-Monoiodothyronamine: the rationale for its action as an endogenous adrenergic-blocking neuromodulator.

Authors:  Heinrich S Gompf; Joel H Greenberg; Gary Aston-Jones; Alexandra G Ianculescu; Tom S Scanlan; Mary B Dratman
Journal:  Brain Res       Date:  2010-07-23       Impact factor: 3.252

Review 4.  The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity.

Authors:  Gregory M Miller
Journal:  J Neurochem       Date:  2011-01       Impact factor: 5.372

Review 5.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

6.  The trace amine associated receptor 1 agonist RO5263397 attenuates the induction of cocaine behavioral sensitization in rats.

Authors:  David A Thorn; Chaogui Zhang; Yanan Zhang; Jun-Xu Li
Journal:  Neurosci Lett       Date:  2014-02-21       Impact factor: 3.046

Review 7.  Dopamine receptors - IUPHAR Review 13.

Authors:  Jean-Martin Beaulieu; Stefano Espinoza; Raul R Gainetdinov
Journal:  Br J Pharmacol       Date:  2015-01       Impact factor: 8.739

8.  Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor.

Authors:  Stefano Espinoza; Ali Salahpour; Bernard Masri; Tatyana D Sotnikova; Mirko Messa; Larry S Barak; Marc G Caron; Raul R Gainetdinov
Journal:  Mol Pharmacol       Date:  2011-06-13       Impact factor: 4.436

9.  Anatomical profiling of G protein-coupled receptor expression.

Authors:  Jean B Regard; Isaac T Sato; Shaun R Coughlin
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

10.  Functional evolution of the trace amine associated receptors in mammals and the loss of TAAR1 in dogs.

Authors:  Eric J Vallender; Zhihua Xie; Susan V Westmoreland; Gregory M Miller
Journal:  BMC Evol Biol       Date:  2010-02-18       Impact factor: 3.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.